Clinical API Development Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a current Good Manufacturing Practice active pharmaceutical ingredient supplied for early-phase and pivotal human clinical manufacturing. The material is released under ICH Q7, FDA 21 CFR 210, FDA 21 CFR 211, and EudraLex Volume 4 Part II, with a supplier model designation documented as CD-API-GMP-01 in certificate-of-analysis metadata. Compendial alignment is maintained to Ph. Eur., USP, and JP general chapters where a monograph exists; where no monograph is available, specification limits are justified under ICH Q6A decision-tree criteria. The API is a crystalline or milled powder with polymorphic form identified by X-ray powder diffraction and stated on the lot certificate. The release test panel includes assay, related substances, residual solvents, water content, residue on ignition, elemental impurities, particle-size distribution, and, for injectable applications, bacterial endotoxin and bioburden. The product is intended for formulation into tablets, hard capsules, granules, oral solutions, and injectable finished dosage forms. The same clinical material may not be directly interchangeable across all dose routes without route-specific qualification because particulate and pyrogen criteria differ.

What Limits Direct Compression Performance in Tablet and Capsule Grades?

For tablet and capsule development, the physical specification is dominated by particle-size distribution, bulk density, tapped density, and flow function. Laser diffraction is performed under USP <429> or ISO 13320 to report D10, D50, and D90. Direct compression blends require a D90 below 500 µm to meet content uniformity expectations under USP <905> or Ph. Eur. 2.9.40, while excessive fines with a D10 below 20 µm can raise cohesive arching in hopper discharge. The span, defined as (D90 − D10)/D50, is monitored because spans above 2.0 have been associated with segregation in rotary tablet press feed frames. Bulk density and tapped density are measured by Ph. Eur. 2.9.34; a bulk density below 0.35 g/cm³ may require force-feeding or granulation for high-speed tablet presses. Flow classification is derived from Hausner ratio and Carr index; flow is considered poor when the Hausner ratio exceeds 1.35. Capsule filling on dosator or tamping-pin machines requires sufficient powder flow for weight uniformity under Ph. Eur. 2.9.5; low-density powders are often densified by roller compaction. Published data for this specific API configuration is limited, so formulation-grade particle-size limits must be set from process capability data.

When direct compression fails due to poor flow or segregation, wet granulation is employed. Clinical API is granulated in high-shear mixers with impeller and chopper speeds selected from laboratory torque curves, then dried in fluid-bed dryers. Loss on drying after granulation is typically controlled at 1.0–3.0% as measured by Ph. Eur. 2.2.32, because lower moisture may reduce granule strength and higher moisture may accelerate agglomeration or polymorph conversion. The milled granule fraction is passed through a screen with aperture size selected to avoid over-granulation, since granule solid fraction above 0.75 in roller-compacted ribbons can reduce tablet tensile strength. For granules intended for capsules, bulk density and flow are adjusted with excipient blends in diffusion mixers or high-shear mixers. Blend uniformity is tested using USP <905> or Ph. Eur. 2.9.40, with acceptance based on relative standard deviation. Tablet compression is performed on rotary presses with compression force monitored; final tablets are evaluated for hardness, disintegration under Ph. Eur. 2.9.1, and dissolution under USP <711> or Ph. Eur. 2.9.3. The granule-specific API is distinguished from direct-compression API by reduced fine-particle content and higher bulk density.

When Injectable Grade APIs Must Meet Particulate and Endotoxin Thresholds

Injectable presentations require route-specific controls for pyrogens, particulates, and sterility assurance. Bacterial endotoxin is measured by the limulus amebocyte lysate test under USP <85> or Ph. Eur. 2.6.14; a representative acceptance criterion for an intravenous API is ≤ 0.5 EU/mg, but the actual limit is derived from the maximum bolus dose and patient body weight. The oral grade is not routinely tested against endotoxin thresholds unless specified. Subvisible particulate matter in the finished injectable is controlled by USP <788>; small-volume parenterals must contain no more than 6000 particles per container at ≥ 10 µm and no more than 600 particles per container at ≥ 25 µm. Large-volume parenterals are limited to 25 particles per mL at ≥ 10 µm and 3 particles per mL at ≥ 25 µm. Solution-grade injectable APIs are often controlled by D90 below 50 µm or are dissolved prior to sterile filtration, making the particle-size limit dependent on the manufacturing process. Water content for lyophilized injectable API may be restricted to ≤ 0.5% to maintain cake structure, measured by USP <921> or Ph. Eur. 2.5.12. Sterility of the finished injection is tested by USP <71> after aseptic processing or terminal sterilization; the API itself may be supplied as a bioburden-controlled non-sterile powder, but bioburden must meet the sterilizing filtration validation under ISO 13408-1 or equivalent. The difference from oral grade is therefore not merely particle size but a full pyrogen, bioburden, and particulate control package.

Relative to non-clinical, food-grade, or research-grade materials, the clinical API is differentiated by GMP quality systems and regulatory submission readiness. The clinical API is manufactured and released with full lot traceability, change control, and stability commitments under ICH Q1A. A Drug Master File or Certificate of Suitability to the Ph. Eur. monographs is maintained for the active ingredient. Non-clinical material designated as laboratory-grade or food-grade is not released under FDA 21 CFR 211 and is not suitable for human dose-form manufacture. Within clinical grades, the distinction between oral and injectable is based on control of endotoxin, bioburden, particulate matter, and residual water. The same chemical entity may be supplied in two physical grades: a direct-compression or granulation grade with bulk density above 0.45 g/cm³ and a solution-grade injectable grade with reduced endotoxin and controlled particle size. The clinical development grade also differs from commercial-grade API by scale and validation status; process validation under FDA 21 CFR 211.100 may be uncompleted at the clinical stage but parameter ranges are recorded to support later process validation. Published data for routine clinical-to-commercial interchange of unvalidated grades is limited, so material qualification is lot-specific.

Residual Solvent and Elemental Impurity Control in Oral and Injectable Clinical Batches

The control of residual solvents and elemental impurities is based on risk assessment tied to the synthetic route and final purification. Residual solvent limits are set according to ICH Q3C. Class 1 solvents such as benzene and carbon tetrachloride are typically excluded; Class 2 solvents are limited to option 1 concentration limits, and Class 3 solvents are limited by the general limit of 5000 ppm or 0.5% as appropriate. Headspace gas chromatography is used with flame ionization detection or mass spectrometry. Elemental impurities are quantified by inductively coupled plasma mass spectrometry under USP <233> and limits are derived from permitted daily exposure values in ICH Q3D. For parenteral products, the elemental impurity risk assessment includes the contribution of the container closure system leachables and the administration route. The API is also tested for residue on ignition under USP <281> and, if specified, microbial contamination of non-sterile products under USP <61> and USP <62>. These controls separate clinical-grade API from research-grade product because they are applied at final release and supported by method validation under ICH Q2(R1).

During clinical development, forced degradation studies establish a stability-indicating method for the API across tablet, capsule, granule, and injection presentations. Forced degradation is conducted with acid, base, peroxide, heat, and light under ICH Q1A and ICH Q1B. The analytical method must demonstrate specificity by resolving all principal degradation products from the API, with quantification limits below the reporting threshold in ICH Q3A. Long-term and accelerated stability storage at 25 °C/60% RH and 40 °C/75% RH is maintained for clinical trial material according to ICH Q1A. Packaging for oral clinical supplies is selected to protect against moisture; for injectable supplies, the API is packaged in low-particulate containers and may require inert gas overlay if the solid is moisture-sensitive. The data generated from these studies form the shelf-life justification for the investigational medicinal product and are included in the Investigational Medicinal Product Dossier.